Cholestasis associated with mesalazine therapy in a patient with Crohn's disease
Authors:
- 1 February 1997
- journal article
- case report
- Published by Elsevier in Journal of Hepatology
- Vol. 26 (2) , 425-428
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Acetylsalicylate (ASA)‐induced mitochondrial dysfunction and its potentiation by Ca2+Liver International, 1994
- Bioavailability of 5-aminosalicylic acid from slow release 5-aminosalicylic acid drug and sulfasalazine in normal childrenDigestive Diseases and Sciences, 1993
- Mesalazine: A Global Safety EvaluationScandinavian Journal of Gastroenterology, 1990
- Peripheral neuropathy and mesalazine.BMJ, 1989
- Adverse reactions to sulphasalazine and 5‐amino salicylic acid in the same patientAlimentary Pharmacology & Therapeutics, 1987
- Salicylate and Mitochondrial Injury in Reye's SyndromeScience, 1983
- Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's DiseaseNew England Journal of Medicine, 1980
- Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.Gut, 1980
- Capacity-limited Gut Wall Metabolism of 5-aminosalicylic acid, a Therapeutically Active Metabolite of Sulfasalazine, in RatsJournal of Pharmaceutical Sciences, 1979
- Sulfasalazine toxic reactions. Hepatitis, fever, and skin rash with hypocomplementemia and immune complexes1978